Endovia Health Sciences (EDVA) Net Cash Flow Growth (1y) (2013 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Net Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | 149.49% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -104.22% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | -56.01% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -56.01% |
| Mar 31, 2026 | 335.56% |
| Dec 31, 2025 | -105.59% |
| Sep 30, 2025 | -43.74% |
| Jun 30, 2025 | 2,286.59% |
| Mar 31, 2025 | 85.40% |
| Dec 31, 2024 | -18.05% |
| Sep 30, 2024 | 143.46% |
| Jun 30, 2024 | 99.46% |
| Mar 31, 2024 | 84.34% |
| Dec 31, 2023 | -84.50% |
| Sep 30, 2023 | 47.88% |
| Jun 30, 2023 | 69.82% |
| Mar 31, 2023 | -155.86% |
| Dec 31, 2022 | 151.39% |
| Sep 30, 2022 | 58.00% |
| Jun 30, 2022 | -137.23% |
| Mar 31, 2022 | 361.86% |
| Dec 31, 2021 | -1,724.16% |
| Sep 30, 2021 | -701.01% |